株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の前立腺癌診断および治療市場 - 成長、動向、予測

Prostate Cancer Diagnostics and Therapy Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 660546
出版日 ページ情報 英文 112 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.06円で換算しております。
Back to Top
世界の前立腺癌診断および治療市場 - 成長、動向、予測 Prostate Cancer Diagnostics and Therapy Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年04月01日 ページ情報: 英文 112 Pages
概要

世界の前立腺癌診断および治療市場は、2018年から2023年にかけて6.1%のCAGRで推移することが予測されています。2016年においては、収益ベースで最大のシェアを占めた北米地域が市場を牽引しました。

当レポートでは、世界の前立腺癌診断および治療市場を調査し、市場の概要、タイプ・診断法・治療法・地域別の市場規模の推移と予測、市場動向、成長要因・阻害要因ならびに市場機会・課題の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第6章 成長要因、阻害要因、市場機会、課題

  • 市場の成長要因
    • 前立腺癌の罹患率の高さ
    • 治療薬の革新とゲノミクスおよびプロテオミクス領域における発展
    • 医薬品開発分野における公的部門および民間部門の資金調達の増加
    • 癌・腫瘍診断および治療薬の技術的発展
  • 市場の阻害要因
    • 診断検査に関連するコストの高さ
    • 臨床試験の成功率の低さ
    • 治療の副作用
  • 市場機会
  • 主な課題

第7章 市場セグメンテーション

  • 種類別
    • 良性前立腺肥大症
    • 前立腺腺癌
    • 小細胞癌
    • その他
  • 診断法別
    • 細胞生検
    • デジタル直腸検査
    • 臨床検査
    • 診断イメージング
  • 治療法別
    • 化学療法
    • 小線源治療
    • 放射線療法
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 中東・アフリカ
    • 南米

第8章 競合情勢

  • 合併・買収分析
  • 合意、コラボレーション、パートナーシップ
  • 新製品の発売

第9章 主要プレーヤー

  • Abbott
  • AstraZeneca
  • アステラス製薬
  • Bayer AG
  • BioMark Diagnostics Inc.
  • Sanofi
  • Ipsen
  • TOLMAR Pharmaceuticals, Inc.
  • Indevus Pharmaceuticals Inc.
  • Dendreon Inc.
  • その他の企業

第10章 市場の将来展望

目次
Product Code: 47468

Market Overview

The prostate cancer diagnostics and therapy market is expected to register a CAGR of nearly 6.1% during the forecast period, 2019-2024.

  • The major factor driving the growth of the market studied is aging population and high prevalence rate of prostate cancer. Prostate cancer is the second most common type of cancer in male population. About 80% of men who reach 80 years of age are diagnosed with it.
  • As per the estimates provided by the American Cancer Society, in 2018, the United States is expected to witness over 164,690 new cases of prostate cancer, with over 29,430 related deaths. Nearly 60% of the total prostate cancer cases diagnosed are among men aged 65 years or older. One in every nine men is expected to be diagnosed with prostate cancer during his lifetime.
  • In addition, according to the United States Census Bureau's Statistics, the total number of people aged 65 and older exceeds 50 million as of 2017, and the number of elderly is projected to increase by almost 18 million during 2020-2030. The number of people aged 85 and older is expected to triple from an estimated 6 million of today to nearly 20 million, by 2060. The risk of developing prostate cancer increases significantly with age, and rise in geriatric population is one of the leading factors that contribute to the expansion of the market.

Scope of the Report

The prostate gland is located in the pelvis, below the bladder and in front of the rectum. Prostate cancer begins when normal cells in the prostate begin to multiply uncontrollably. The scope of the study is limited to revenue generated by various diagnostic and therapeutic products used in the management of benign prostatic hyperplasia, prostatic adenocarcinoma, and small cell carcinoma, among other types of prostate cancer.

Key Market Trends

The Prostate-specific Antigen (PSA) Testing Segment is Expected to Grow at Rapid Pace.

Prostate-specific Antigen (PSA) is a protein produced by prostate cells. Therefore, the PSA test is performed to diagnose prostate cancer (PCa) in men and for follow-up post treatment to check if the cancer relapses. PSA testing is an important tool for detecting prostate cancer, which measures the level of PSA in a man's blood. Medicare and several private insurers provide coverage for an annual PSA test for all Medicare-eligible men aged 50 and older. The PSA testing is gaining popularity among clinicians and hospitals, owing to the increasing number of people being affected by prostate cancer. It has more market value in the countries with high prevalence rate (Western) and low prevalence rate (Asian), as PSA is used globally for the early detection/screening of prostate cancer.

PSA testing is anticipated to reduce the likelihood of death from prostate cancer. Refinements of the prostate-specific antigen (PSA) test have been developed to reduce the number of false positive results. Therefore, due to the rising prevalence of prostate cancer, the market is expected to witness high growth rate, over the forecast period.

United States is Expected to Retain the Largest Market Share During the Period of Forecast.

Prostate cancer is considered as one of the most common cancers among American men, and more than 60% of all prostate cancers are diagnosed in men older than 65. According to the American Cancer Society's, 2019, there are about 174,650 new cases of prostate cancer accounting for 31,620 deaths. Hence, it is considered to have an early diagnosis of the condition. In case of the treatment, the early stages of prostate cancer are treated by radiation therapy and for the late stages, where it has spread beyond the prostate gland, hormone therapy, chemotherapy, and or immunotherapy treatments, are recommended. In the case of benign prostatic hyperplasia (BPH), resectoscopy is the major treatment procedure. Zytiga and Xtandi are the major therapeutics that are used for treatment. Zytiga is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). With promising pipeline drugs, such as Apalutamide, the market of therapeutics is expected to increase.

Competitive Landscape

Several large drug and equipment manufacturers exist within the global prostate cancer diagnostic and therapy market, and their status as a major player lies primarily within specific product markets. Key players in the market include Abbott Laboratories, Astellas Inc., AstraZeneca, Bayer HealthCare AG, Cellanyx Diagnostics Inc, Dendreon Corporation, Ferring Pharmaceuticals, Ipsen Group, Sanofi-Aventis, Tolmar Inc, GE Healthcare, Siemens Healthineers, and F. Hoffmann-La Roche AG, among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Aging Population and High Prevalence Rate of Prostate Cancer
    • 4.2.2 Innovation in Drugs and Developments in Genomics and Proteomics
    • 4.2.3 Increasing Government Initiatives for Cancer Awareness
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Prostate Cancer Drugs
    • 4.3.2 Low Success Rate of Clinical Trials
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Benign Prostatic Hyperplasia
    • 5.1.2 Prostatic Adenocarcinoma
    • 5.1.3 Small Cell Carcinoma
    • 5.1.4 Other Types
  • 5.2 By Modality
    • 5.2.1 Diagnosis
      • 5.2.1.1 Tissue Biopsy
      • 5.2.1.2 Transrectal Ultrasound
      • 5.2.1.3 Clinical Laboratory Examination
      • 5.2.1.3.1 Prostate-specific Antigen Testing
      • 5.2.1.3.2 Urine Testing
      • 5.2.1.4 Diagnostic Imaging
    • 5.2.2 Treatment
      • 5.2.2.1 Surgery
      • 5.2.2.2 Radiation Therapy
      • 5.2.2.3 Therapeutics
      • 5.2.2.3.1 Hormone Therapy
      • 5.2.2.3.2 Chemotherapy
      • 5.2.2.3.3 Other Treatments
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Ipsen SA
    • 6.1.2 Bayer AG
    • 6.1.3 Astellas Pharma Inc.
    • 6.1.4 Abbvie Inc.
    • 6.1.5 Dendreon Pharmaceuticals LLC
    • 6.1.6 AstraZeneca PLC
    • 6.1.7 Sanofi-Aventis
    • 6.1.8 Tolmar Inc.
    • 6.1.9 Koninklijke Philips NV
    • 6.1.10 Hologic Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top